Top NYC, NY Health Tech Companies With Best Stability & Growth (638)

Investor Backing & Capital Strength: A ~$100M raise in July 2024 at a ~$2.3B valuation—about double the prior year—signals strong investor confidence and provides resources to scale. Leadership also cited a clear line of sight to company‑level profitability.

Strong Market Position & Advantage: A provider network approaching 50,000 versus a key rival’s ~17,000, plus 6,000,000+ hours of care and 1,000,000 patients in 2024, indicate scaled utilization and reach. Such scale supports competitive differentiation in insurance‑enabled behavioral health.

Market Expansion: Expansion into Medicare Advantage with Medicaid planned for 2025 and nationwide integrated primary‑care‑to‑mental‑health referrals broaden the addressable market. Payer expansion alongside network growth supports demand capture.

Profitability: Signals indicate the company returned to profitability by 2023 and maintained profitable growth into 2024–2025, reflecting increased financial stability.

Strong Market Position & Advantage: Public materials portray the firm as a category leader in U.S. consumer doctor discovery and real-time booking, operating at national scale with millions of bookings.

Strategic Partnerships: Recent integrations with organizations like Blue Shield of California, Healthgrades, Yelp, and large health systems expand distribution and reinforce platform reach.

Investor Backing & Capital Strength: Fresh capital includes a $50M Series D on April 9, 2026 led by Boehringer Ingelheim and a 2025 Series C with Dassault Systèmes/Medidata to fund commercialization and platform scaling. Feedback suggests these transactions reflect strong external confidence and provide runway to advance regulatory and launch efforts.

Product Line Growth: Multiple FDA authorizations (Rejoyn in 2024; CT‑132 in 2025), positive Phase 3 data for CT‑155, and acquisition of Better Therapeutics’ assets expand the portfolio across psychiatry, neurology, and cardiometabolic conditions. A 2026 Ultrahuman partnership further extends migraine technology into adjacent offerings.

Strategic Partnerships: Multi‑year collaborations with Boehringer Ingelheim and Otsuka, plus ecosystem ties with Dassault Systèmes/Medidata and Ultrahuman, underpin development and prospective commercialization. These alliances distribute risk and provide capabilities and channels that many peers lack.

Diversified Revenue Streams: Non‑COVID portfolio momentum across oncology, vaccines, and cardiovascular is contributing, with Eliquis, Prevnar, Vyndaqel, and Seagen‑derived assets cited as growth drivers. This breadth helps offset the normalization of COVID products.

Cost & Operational Efficiency: Adjusted diluted EPS rose in 2025 versus 2024, attributed to cost realignment and mix. Ongoing cost‑saving and manufacturing optimization programs are intended to support margins through mid‑decade.

Future-Ready Strategy: Management highlights oncology and next‑generation assets, with Seagen’s ADC platform and pending data/approvals expected to support medium‑term growth. Pipeline catalysts into 2026 position the company for potential re‑acceleration if execution lands as planned.

Investor Backing & Capital Strength: Feedback suggests a $30M Series A in 2022 led by Optum Ventures with participation from Cigna Ventures provides meaningful runway for execution. This capital underpins the pivot and subsequent product buildout.

Future-Ready Strategy: After divesting its TPA unit in October 2023, the company refocused on a healthcare data/AI platform (Relay) with enterprise-grade controls (SOC 2 Type II, HIPAA alignment, HITRUST), targeting payer/TPA needs. This sharpened software focus typically supports more scalable, higher‑margin growth.

Product Line Growth: The launch of the Relay integration platform (March 2023) and expanded modules/use cases on the site/docs indicate continued product development. Recent case studies and content, alongside selective hiring, suggest active build-and-sell motion.

Product Line Growth: Multiple AI- and automation-led offerings—Cedar Cover, the Kora AI voice agent, and expanded Cedar Intelligence personalization—signal active product investment and broader platform scope into 2025–2026. These launches indicate sustained feature velocity beyond core billing.

Market Expansion: Cedar cites 50 million patients served, 1.5 billion interactions, and $10 billion in payments processed, pointing to a materially larger footprint than in 2022. Scale signals alongside the April 2026 Cedar Intelligence launch suggest broader reach and usage across the platform.

Strategic Partnerships: New wins with Sanford Health and LCMC Health, plus momentum among athenaOne practice groups, show ongoing commercial traction and channel reach. These announcements indicate continued access to large enterprise environments and mid‑market physician groups.

Strong Revenue Growth: Reported total net revenue rose from $693.4 million in 2024 to about $1.27 billion in 2025, with Q4 2025 also showing strong year‑over‑year growth. Management guides 2026 revenue to roughly $1.59 billion, indicating continued expansion.

Customer Loyalty & Retention: Disclosed net revenue retention of approximately 126% and total remaining contract value exceeding $1.1 billion signal expanding multi‑year demand. These metrics indicate existing customers are increasing spend and extending commitments.

Strategic Partnerships: Multi‑year collaborations with major pharmas and health systems—including a three‑year, $200 million data/modeling agreement with AstraZeneca/Pathos and an expanded Merck collaboration—support growth in data licensing and AI applications. Partnerships with top‑tier sponsors evidence strong demand for the platform.

Market Expansion: Recent company and LinkedIn posts highlight launches or restarts of new teams in Grand Rapids and Mid‑Michigan alongside activity across multiple states, indicating selective geographic growth in 2026. The company’s site also notes it has launched in multiple states with a tech‑enabled model for high‑need SMI populations.

Investor Backing & Capital Strength: The company has secured substantial funding, including a $28.1M round led by GV in 2023 and an additional round reported in 2025, providing capital to support expansion efforts. These financings underscore continued access to growth capital during rebuilding.

Strategic Partnerships: Materials and trade press describe payer relationships across multiple states, with collaborations tied to Medicaid managed‑care contracts and references to partners such as Molina and Carelon. Such arrangements underpin a contract‑driven growth model when conditions allow.

Profitability: Results indicate improved profitability in 2025, with management emphasizing margin quality as the mix shifts toward higher‑margin offerings. Guidance and commentary describe deliberate trade‑offs to favor profitability over scale.

Product Line Growth: Pharma Manufacturer Solutions/“Pharma Direct” expanded rapidly in 2025 and was cited as a key driver of results. Management also highlighted emerging subscriptions and Employer Direct as longer‑term growth vectors.

Diversified Revenue Streams: The business is increasingly balanced between manufacturer solutions, select subscriptions, and employer offerings rather than relying solely on prescription transactions. This mix shift supports stronger unit economics even if total revenue growth is muted.

Strategic Partnerships: Public partnerships with MetLife, New York Life, Securian, and others—along with the insurer coalition formed via the “Empathy Alliance”—point to deep carrier integrations and strong distribution leverage. These relationships indicate large carriers are standardizing on Empathy for post‑claim experience in the U.S. life channel.

Investor Backing & Capital Strength: Closing a $72M Series C in May 2025 (total funding roughly $162M) with participation from top VCs and major insurers signals strong financial support. This unusual mix of capital and distribution partners provides resources and validation for scaling in a young category.

Market Expansion: Geographic expansion into Canada and the U.K., with partnerships such as Sun Life, TD Bank, and BMO Insurance, shows momentum beyond the U.S. base. Additional carrier deals and claims coverage across North America broaden reach into tens of millions of policyholders.

Investor Backing & Capital Strength: Recent announcements of a $32M Series A (March 2024) and an oversubscribed $50M Series B (April 2025, including $20M credit) indicate strong access to capital. These rounds are positioned to fund product expansion, go‑to‑market, and hiring.

Strategic Partnerships: The TriNet collaboration (October 2023, highlighted again in May 2025) and joining the Workday Wellness Program (April 2026) show expanding distribution through major HR platforms. These channels enhance reach into SMB and broader employer segments.

Market Expansion: Company communications and coverage cite surpassing 15,000 customers and momentum in the mid‑market. Channel distribution via platforms like TriNet is presented as widening access to employer groups.

Investor Backing & Capital Strength: Fresh funding in late 2024 following a prior raise indicates continued investor support and runway extension. Feedback suggests this capital has underpinned ongoing product launches and commercial activity into 2025–2026.

Product Line Growth: The company has continued to ship new capabilities such as monitoring/Signal‑style alerts, validation tooling, and other interoperability offerings. Feedback suggests this reflects an active roadmap and sustained execution rather than stagnation.

Market Expansion: Particle promotes broad national connectivity across major exchange networks and state HIEs, with TEFCA alignment via participation under a QHIN. These moves point to expanding reach and increasing utility for customers.

Market Expansion: Headcount and office disclosures show an expansion from 35+ to 40+ offices, alongside new capacity such as the Hyderabad Operations Center. These moves indicate a broader global presence to meet demand.

Strong Hiring & Retention: Recent materials cite 2,783 new hires in 2024 and over 2,850 promotions, with labor‑market analytics indicating year‑over‑year headcount growth through 2025. These suggest sustained talent investment and scaling.

Innovation-Driven Growth: Creation of a dedicated Platform & Products unit and scaling of ZAIDYN/Max.AI signal a push toward scalable, AI‑enabled offerings. Acquisitions such as Digital Additive (2024) and Torrent Consulting (2025) further broaden Salesforce and AI capabilities.

Investor Backing & Capital Strength: A large late‑stage funding round led by prominent investors at a high valuation indicates strong capital support and confidence. Disclosures note the capital is allocated to scale core analytics, navigation, and incentives capabilities.

Strong Revenue Growth: Company communications and trade coverage consistently cite triple‑digit year‑over‑year revenue growth. This momentum is presented alongside broader traction markers around the funding announcement.

Market Expansion: Information provided indicates reach to millions of members across hundreds of organizations, spanning employers, plans, and providers. References to new channels and programs suggest a widening commercial footprint.

Investor Backing & Capital Strength: Funding announcements in 2025, including a large Series B led by Insight Partners and substantial total capital cited, signal strong financial capacity to scale. Named investors and board participation are presented as validation of execution and expansion potential.

Innovation-Driven Growth: The launch of a unified AI-powered senior-living ecosystem spanning safety, eCall, workflow, and analytics, alongside recognitions such as Fast Company’s 2026 list and DHNY 2025, reflects product-led momentum. Operator case materials and investor commentary cite meaningful operational improvements tied to this platform approach.

Market Expansion: Deployments across 100+ communities with roughly 30 operators and new 2026 multi-community rollouts (e.g., Watercrest) indicate a growing senior-living footprint. Public alliances and named operator partnerships suggest increasing reach across geographies and portfolios.

Investor Backing & Capital Strength: Recent funding led by Andreessen Horowitz and a disclosed Series B provide fresh capital and visible investor confidence. The company links this capital to planned expansion across additional care settings and broader U.S. reach.

Market Expansion: Operating presence across many states, rising claims throughput, and stated plans to grow into home health, long‑term care, and substance use disorder point to ongoing geographic and segment expansion. Company materials cite increasing footprint and scale since its February 2025 launch.

Innovation-Driven Growth: An AI‑driven reimbursement platform reporting high first‑pass claims acceptance and fewer denials indicates product performance that can support scaling. Case examples and platform claims suggest the technology is enabling faster, more accurate payments and broader adoption.

Investor Backing & Capital Strength: Recent late-stage funding rounds and a higher valuation are presented as clear signals of substantial capital support and investor confidence. The company indicates plans to deploy this capital toward team growth and product development across core markets.

Strong Revenue Growth: Management reports crossing a major ARR milestone with multiple years of rapid top-line expansion. Consistent year-over-year acceleration is highlighted alongside continued scaling plans.

Market Expansion: The business is extending beyond housing into healthcare and signaling international ambitions. New office hubs and active hiring across functions support broader geographic and vertical reach.

Investor Backing & Capital Strength: Successive raises since 2024, including a recently reported $65M round in March 2026, indicate strong access to capital to fund product and go‑to‑market expansion.

Market Expansion: EHR integrations covering a large share of senior living (ALIS/ECP/Yardi live with PointClickCare and August Health on the roadmap) and references to deployments across hundreds of communities signal widening distribution and access to customers.

Innovation-Driven Growth: An expanding platform (Sage Core, Detect, Insight) and new workflow features suggest product breadth and AI‑enabled capabilities that support differentiated growth beyond point solutions.

Strong Revenue Growth: 2025 results show total revenue increased meaningfully year over year, with software higher and drug‑discovery contributions expanding. Management also guides continued expansion into 2026 as measured by software ACV.

Strategic Partnerships: Large, multi‑target collaborations (e.g., with Novartis) and integrations with leading pharmas (e.g., Lilly) reinforce commercial traction and ecosystem reach. These relationships support both recurring software usage and potential milestone‑driven upside.

Future-Ready Strategy: Accelerating the shift from on‑premise to hosted licensing is intended to make revenue more predictable and better align recognition with contract value. 2026 priorities emphasize platform scaling, new offerings like predictive toxicology, and deeper partner integrations.

Investor Backing & Capital Strength: A $120M funding round announced on June 18, 2024 is highlighted as a strong proxy for expansion capacity. TechCrunch’s year-end recap lists AKASA among U.S. AI startups that raised $100M+ in 2024.

Strategic Partnerships: Cleveland Clinic rolled out AKASA’s AI coding tools systemwide in early 2025 and expanded to a CDI solution across all U.S. locations by October 13, 2025. An Oracle Cerner collaboration broadens access to AKASA’s automation for EHR customers.

Market Expansion: AKASA’s site states its client base represents 650+ hospitals and 6,500+ outpatient facilities across all 50 states. Named customer outcomes such as Nebraska Methodist’s reported $2M+ gross revenue lift and the upsell within Cleveland Clinic indicate footprint growth and upsell potential.